Open AccessThe efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR
Author(s) -
SG Ashwell,
JS Bevan,
O M Edwards,
MM Harris,
C Holmes,
MA Middleton,
RA James
Publication year - 2004
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.0.1500473
Subject(s) - acromegaly , medicine , octreotide , adverse effect , endocrinology , gastroenterology , somatostatin , growth hormone , hormone
Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume <0.5 ml. The aim of this study was to establish the efficacy and safety of Autogel in patients with acromegaly previously treated with octreotide LAR.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom